Cargando…
Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
Obeticholic acid (OCA), the first FXR-targeting drug, has been claimed effective in the therapy of liver fibrosis. However, recent clinical trials indicated that OCA might not be effective against liver fibrosis, possibly due to the lower dosage to reduce the incidence of the side-effect of pruritus...
Autores principales: | Zhou, Jiyu, Huang, Ningning, Guo, Yitong, Cui, Shuang, Ge, Chaoliang, He, Qingxian, Pan, Xiaojie, Wang, Guangji, Wang, Hong, Hao, Haiping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542786/ https://www.ncbi.nlm.nih.gov/pubmed/31193776 http://dx.doi.org/10.1016/j.apsb.2018.11.004 |
Ejemplares similares
-
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2020) -
Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis
por: Wang, Hong, et al.
Publicado: (2018) -
Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
por: Goto, Toshihiro, et al.
Publicado: (2018) -
Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016) -
Obeticholic acid for primary biliary cholangitis
Publicado: (2020)